COMMUNIQUÉS West-GlobeNewswire

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
04/08/2026
-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of other pending [...]
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
04/08/2026
TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase 2 clinical trial of [...]
Milestone Scientific Announces Strategic Federal Distribution Partnership with Red One Medical to Expand Commercial Access for the CompuFlo® Epidural System
04/08/2026
Partnership Expands Commercial Reach Across VA, Department of Defense and Other Federal Healthcare Systems ROSELAND, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a medical [...]
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
04/08/2026
MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) ( Nasdaq: RNXT ), a life sciences company developing innovative targeted oncology therapies and commercializing [...]
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
04/08/2026
Dose-finding Phase 1b study (n=240) on track for topline data in September 2026 CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1 class CRB-913 [...]
Carbonium Core Reports Rare Earth and Critical Mineral Content in Initial Sample Assay
04/08/2026
Multi-element analysis returns elevated concentrations of both light and heavy rare earth elements, along with a broad suite of industrial metals FREDERICK, Md., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental [...]
Beacon Behavioral Partners Expands National Footprint with First Georgia Partnership
04/08/2026
Physician-led partnership deepens access to behavioral healthcare through partnership with AR Psychiatric & Counseling Center Georgia and strengthens its growing behavioral health network across the nation PLANO, [...]
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
04/08/2026
Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain Strengthens Autonomix’s platform opportunity across oncology, autonomic [...]
ABLi Therapeutics Announces Outcomes from its Parkinson’s-related Biomarker Study Demonstrating Modification of Human Disease with Risvodetinib
04/08/2026
11 tissue, blood, and cerebrospinal fluid biomarkers reflecting the biological cascade of neurodegeneration and neuroinflammation in PD respond in concert to risvodetinib treatment in patients with early untreated [...]
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
04/08/2026
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization NORCROSS, Ga [...]
Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech Innovators
04/08/2026
Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing capabilities serving global medical device innovators Marks completion of [...]
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
04/08/2026
Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development [...]
Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL‑051 for Refractory Autoimmune Diseases
04/08/2026
-- First‑in‑human trial of Oblenio’s sole asset, a CD19×BCMA×CD3 tri‑specific T‑cell engager, moves forward to rapidly generate broad proof of concept -- NANJING, China, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads [...]
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
04/08/2026
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases [...]
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
04/08/2026
NTAP Designation Expected to Support Medicare Patient Access, Treatment Center Economics and Commercial Adoption CLEVELAND, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage [...]
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
04/08/2026
First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for a planned [...]
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
04/08/2026
WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion Phase [...]
Tecan schedules conference call on August 11th to discuss half year 2026 financial results
04/08/2026
Männedorf, Switzerland, August 4, 2026 – The Tecan Group AG (SIX Swiss Exchange: TECN) will hold a conference call to discuss the financial results for the first half year 2026 on Tuesday, August 11th, 2026, at 09:00 [...]
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
04/08/2026
New agreement builds on commercialization and development of precision-fermented dairy proteins and enzymes while reinforcing Dyadic's diversified commercialization strategy JUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE [...]

Pages